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Abstract
Purpose: As has been previously reported, the somatostatin receptor (SSTR) imaging agent
[68Ga]-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid-d-Phe(1)-Tyr(3)-
octreotate ([68Ga]DOTATATE) demonstrates lower uptake in normal organs in patients with a
high neuroendocrine tumor (NET) burden. Given the higher SSTR affinity of [68Ga] DOTATATE,
we aimed to quantitatively investigate the biodistribution of [68Ga]-labeled 1,4,7,10-tetraazacy-
clododecane-N,N′,N″,N‴-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ([68Ga]DOTATOC) to deter-
mine a potential correlation between uptake in normal organs and NET burden.
Procedures: Of the 44 included patients, 36/44 (82 %) patients demonstrated suspicious
radiotracer uptake on [68Ga] DOTATOC positron emission tomography (PET)/X-ray computed
tomography (CT). Volumes of interest (VOIs) were defined for tumor lesions and normal organs
(spleen, liver, kidneys, adrenals). Mean body weight corrected standardized uptake value
(SUVmean) for normal organs was assessed and was used to calculate the corresponding mean
specific activity uptake (Upt: fraction of injected activity per kg of tissue). For the entire tumor
burden, SUVmean, maximum standardized uptake value (SUVmax), and the total mass (TBM)
was calculated and the decay corrected tumor fractional uptake (TBU) was assessed. A
Spearman’s rank correlation coefficient was used to determine the correlations between normal
organ uptake and tumor burden.
Results: The median SUVmean was 18.7 for the spleen (kidneys, 9.2; adrenals, 6.8; liver, 5.6).
For tumor burden, the median values were SUVmean 6.9, SUVmax 35.5, TBM 42.6 g, and TBU
1.2 %. With increasing volume of distribution, represented by lean body mass and body surface
area (BSA), Upt decreased in kidneys, liver, and adrenal glands and SUVmean increased in the
spleen. Correlation improved only for both kidneys and adrenals when the influence of the tumor
uptake on the activity available for organ uptake was taken into account by the factor 1/(1-TBU).
TBU was neither predictive for SUVmean nor for Upt in any of the organs. The distribution of
organ Upt vs. BSA/(1-TBU) were not different for patients with minor TBU (G3 %) vs. higher TBU
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(97 %), indicating that the correlations observed in the present study are explainable by the body
size effect. High tumor mass and uptake mitigated against G1 NET.
Conclusions: There is no significant impact on normal organ biodistribution with increasing tumor
burden on [68Ga] DOTATOC PET/CT. Potential implications include increased normal organ
dose with [177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide and decreased absolute lesion detection with
[68Ga] DOTATOC in high NET burden.
Key words: Quantification, [68Ga]DOTATOC, Neuroendocrine tumor, SSTR-PET, Theranostics,
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Introduction
Due to the recently published results of the NETTER-1 trial
[1], Peptide Receptor Radionuclide Therapy (PRRT) is now
US Food and Drug Administration approved and is
becoming a clinical standard for the treatment of metastatic
somatostatin receptor (SSTR)-expressing tumors [2, 3].
Sufficient uptake in neuroendocrine tumor (NET) lesions
must be present on a pretherapeutic SSTR positron emission
tomography (PET) scan using dedicated PET imaging
agents, such as Ga-68 labeled 1,4,7,10-tetraazacyclodode-
cane-N,N′,N″,N‴-tetraacetic acid-d-Phe(1)-Tyr(3)-octreo-
t ide /−oc t reo ta t e ( [ 6 8Ga]DOTATOC/−TATE) or
[68Ga]DOTA,1-Nal3-octreotide ([68Ga]DOTANOC) [4] in
order for patients to potentially benefit from PRRT.
Additionally, increasing interest in quantification of SSTR-
targeted PET has come from recognition that quantitative
uptake parameters might hold the potential to differentiate
between responders and non-responders undergoing PRRT
[5]. However, the biodistribution of a metabolic or receptor-
targeting radiopharmaceutical agent is not in a Bsteady
state,^ but is instead prone to a continuous complex
interplay of uptake, retention, and excretion in both tumor
lesions and non-affected organs with relevant SSTR expres-
sion on the cell surface [6]. Consequently, further insights
into quantitative uptake parameters on SSTR-targeted PET
among patients with different tumor burdens are needed.
One aspect of the interpretation of tumor molecular
imaging is the influence of tumor uptake on the normal
organ biodistribution. High tumor uptake can lead to a
significant decrease in radiotracer uptake in other organs
such as the kidneys [7, 8]. Beauregard et al. studied this
phenomenon using the SSTR imaging agent [68Ga] DOTA-
TATE in a cohort of ten patients with varying tumor burden.
They reported that higher tumor burden correlated with
lower uptake in normal organs and suggested adapting the
therapeutic activity to the tumor load [9].
In the present study, we quantitatively investigated the
biodistribution of [68Ga] DOTATOC to determine if a
correlation between uptake in normal organs and tumor
burden exists and if tumor uptake in PET could theoretically
be used to modify the therapeutic administered activity of
[177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide ([177Lu]DOTA-
TOC). Such a correlation might also have implications for
diagnostic image interpretation. Apart from that, we aimed
to elucidate if a relationship between histological derived
tumor grade and the activity distribution exists and if the
tumor stage can be reproduced from the information
deduced from PET imaging.
Materials and Methods
Medical reports of 44 consecutive patients with histopatho-
logically proven NET grade 1 or 2 who underwent [68Ga]
DOTATOC PET/X-ray computed tomography (CT) imaging
were reviewed in this retrospective evaluation. Of these
patients, 36/44 (82 %) had clinical PET/CT reads indicating
the presence of suspicious, non-physiological radiotracer
uptake compatible with sites of NET. At the time of
imaging, all patients had signed written informed consent
to the medical examination and to the retrospective use of
the anonymized data. Requirement for additional approval
for this analysis was waived due to the retrospective
character of this study.
Imaging Procedure
All patients underwent [68Ga] DOTATOC PET/ CT, with
application of contrast media in 42/44 (95.5 %) according to
current guidelines for the assessment of SSTR expression
[10]. Integrated PET/CT using a Siemens Biograph 64
(Siemens Medical Solution, Erlangen, Germany) operating
in 3D emission mode with CT attenuation correction was
performed in all patients. [68Ga] DOTATOC (median,
125 MBq, 3.4 mCi) was injected intravenously and after
60 min, acquisitions from the mid-thigh to the vertex of the
skull were conducted, covering six to eight bed positions
(depending on patient height) with patients in the supine
position. All data was reconstructed using iterative algo-
rithms implemented by the manufacturer. For further details,
please refer to [11].
Image Analysis
PET images were analyzed using XD3 Software (Mirada
Medical, Oxford, UK). PET, CT, and hybrid PET/CT
imaging overlay were assessed in all 44 patients. Lesions
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were identified as abnormal foci of radiotracer uptake above
background and in expected patterns based on the patients’
original tumor histologies. Lesions were selected by a single
reader and verified by a second reader.
With the normal biodistribution of [68Ga] DOTATOC, at
least moderate uptake is typically observed in spleen, liver,
both kidneys, and both adrenal glands [12]. For these
organs, volumes of interest (VOIs) were manually drawn
covering the entire organ volume using the best visual
approximation of the organ edge on the PET images as has
previously been described [13, 14]. In addition, the entire
volume of all [68Ga]DOTATOC-avid tumor lesions (i.e.,
tumor burden) was manually segmented using the same
procedure. As shown in [14], the CT images were not used
to guide delineation of the VOIs, except in the case of
patients with liver metastases in which liver lesions and
normal liver tissue were carefully separated using PET, CT,
and hybrid PET/CT, as necessary.
The following parameters were assessed for the normal
organs: the mean body weight corrected standardized uptake
value (SUVmean) was measured for the spleen and the liver
as well as for both kidneys and both adrenal glands for
which the final values were derived as mean values of the
right and left organs. The SUVmean were used to calculate
the corresponding mean specific activity uptake (Upt:
fraction of injected activity per kg of tissue).
For the entire tumor burden, SUVmean and maximum
standardized uptake value (SUVmax) as well as the total mass
(TBM) and the decay corrected tumor fractional uptake
(TBU) were determined. TBU was calculated as sum of the
Table 1.. Patient’s characteristics according to grading
Case Sex Age (years) GEP-NET (Y = yes, N = no) VOI localization on baseline SSTR-targeted PET Prior therapy Grading
#1 f 62 Y n/a Surgery 1
#2 m 52 Y n/a Surgery 1
#3 m 55 Y n/a Surgery 1
#4 m 31 Y n/a Surgery 1
#5 m 56 Y n/a None 1
#6 m 60 Y n/a Surgery 1
#7 f 79 Y n/a None 1
#8 f 72 N (CUP) LN, bone, liver, soft tissue Surgery, SSA, CTx, TKI 1
#9 m 76 N (CUP) LN, liver, bone SSA 1
#10 f 51 Y LN, bone, liver Surgery, SSA, PRRT 1
#11 f 73 Y LN SSA 1
#12 m 47 N (lung NET) Lung None 1
#13 f 77 Y Soft tissue Surgery, SSA, CTx 1
#14 m 83 Y Soft tissue SSA 1
#15 f 44 Y Bone None 1
#16 m 75 N (CUP) LN, soft tissue Surgery, SSA 1
#17 f 77 Y LN, bone, liver, soft tissue SSA, PRRT, CTx 1
#18 m 65 Y LN, liver, soft tissue Surgery, SSA, PRRT, CTx 1
#19 f 61 Y Liver Surgery, SSA 1
#20 f 58 Y Bone, liver, soft tissue Surgery, SSA, PRRT 1
#21 m 53 Y LN, bone, soft tissue PRRT 1
#22 m 67 N (CUP) Soft tissue Surgery, CTx 2
#23 f 50 N (lung NET) Soft tissue None 2
#24 m 74 Y Liver Surgery 2
#25 m 67 Y LN, bone Surgery, SSA, PRRT, LP 2
#26 f 42 Y LN, liver Surgery 2
#27 m 57 Y Liver, soft tissue SSA, PRRT 2
#28 f 69 Y LN, bone, lung SSA, PRRT, LP 2
#29 m 64 Y Liver PRRT 2
#30 f 68 Y LN Surgery 2
#31 m 70 Y LN, liver, soft tissue SSA, PRRT, CTx 2
#32 f 72 Y Liver, soft tissue Surgery, SSA, PRRT, CTx 2
#33 f 74 Y Liver, soft tissue Surgery, SSA 2
#34 m 66 Y Liver, soft tissue None 2
#35 m 52 Y LN, liver, soft tissue SSA, PRRT 2
#36 f 63 Y Soft tissue Surgery 2
#37 m 65 Y LN, bone, liver, soft tissue Surgery, SSA, PRRT 2
#38 m 57 Y LN, liver, soft tissue Surgery, SSA 2
#39 f 51 Y Liver, soft tissue Surgery 2
#40 f 49 Y LN, liver SSA, PRRT 2
#41 m 77 Y LN, soft tissue Surgery 2
#42 f 61 Y n/a Surgery 2
#43 f 53 Y Bone Surgery, SSA, PRRT, CTx, LP 2
#44 m 72 Y Liver Surgery 2
CTx chemotherapy, CUP cancer of unknown primary, f female, GEP-NET gastroenteropancreatic neuroendocrine tumor, LN lymph node, m male, LP
locoregional procedure, PRRT peptide receptor radionuclide therapy, RTx radiation therapy, SSA somatostatin analog, SSTR-targeted PET somatostatin
receptor-targeted positron emission tomography
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products [lesion mass / body mass × SUVmean] of all
evaluated tumor lesions assuming density 1 g/cm3 for tumor
lesions. Metastases smaller than 15 mm (G 1.7 cm3) were not
included in the calculation of SUV statistics to avoid partial
volume effects (PVE).
The volume of distribution influences the mean activity
concentration in the body and thus potentially activity
uptake in organs and tumors. Following the procedure in
[9], James’ lean body mass estimate (LBM) and Mostel-
ler’s body surface estimate area (BSA) were used as
surrogate parameters for the volume of distribution [15,
16].
Moreover, to investigate whether tumor grading (G1 vs.
G2) can be confirmed non-invasively by PET, a potential
relationship between tumor grading and the activity distri-
bution was examined.
Table 2.. Descriptive statistics of normal organs and tumor burden
Compartment Parameter Patients Minimum Median Maximum Mean* StDev*
Spleen SUVmean 42 3.6 18.7 36.9 18.7 7.3
Kidneys SUVmean 44 3.2 9.2 19.7
Adrenal glands SUVmean 43 0.5 6.8 13.3 6.7 2.3
Liver SUVmean 44 2.4 5.6 14.6
Tumor burden SUVmean 35 1.6 6.9 36.7
SUVmax 35 4.3 35.5 109.4
TBM 36 2.2 g 42.6 g 3190 g
TBU 36 0.01 % 1.2 % 27.7 %
Maximum/mean standardized uptake value (SUVmax/mean), total tumor mass (TBM), and the decay-corrected tumor fractional uptake (TBU). Asterisk indicates
that mean and standard deviation (StDev) are not shown when the Shapiro-Wilk test excluded a normal distribution. Two spleens could not be assessed due to
splenectomy. In one patient, both adrenal glands were unidentifiable. One patient with only two small lesions G15 mm was excluded from SUV statistics
Table 3.. Correlation between parameters
Parameter Kidneys Spleen Liver Adrenals
SUVmean Upt SUVmean Upt SUVmean Upt SUVmean Upt
Kidneys SUVmean ρ .48 0.17 0.13
P 0.001 0.27 0.41
N 42 44 43
Upt ρ 0.38 0.26 0.48
P 0.01 0.08 0.001
N 42 44 43
Spleen SUVmean ρ 0.61 0.21
P 2E−5 0.19
N 42 41
Upt ρ 0.67 0.25
P 1E−6 0.11
N 42 41






TBU ρ − 0.29 − 0.09 − 0.40 − 0.14 0.09 0.27 − 0.32 − 0.09
P 0.06 0.58 0.008 0.39 0.56 0.08 0.04 0.59
N 44 44 42 42 44 44 43 43
LBM ρ 0.19 − 0.45 0.37 − 0.15 0.18 − 0.34 0.23 − 0.35
P 0.22 0.002 0.02 0.34 0.24 0.03 0.14 0.02
N 44 44 42 42 44 44 43 43
LBM 1-TBU ρ 0.11 − 0.52 0.29 − 0.19 0.22 − 0.27 0.12 − 0.41
P 0.49 3E−4 0.06 0.23 0.16 0.07 0.46 0.007
N 44 44 42 42 44 44 43 43
BSA ρ 0.22 − 0.44 0.34 − 0.23 0.13 − 0.43 0.24 − 0.39
P 0.14 0.003 0.03 0.14 0.42 0.004 0.12 0.009
N 44 44 42 42 44 44 43 43
BSA 1-TBU ρ 0.06 − 0.57 0.21 − 0.28 0.19 − 0.32 0.03 − 0.49
P 0.69 5E−5 0.19 0.07 0.22 0.03 0.85 8E−4
N 44 44 42 42 44 44 43 43
Spearman’s rho (ρ), the two-sided significance P (bold for significant correlations), and the number N of patients included are shown
SUVmean mean standardized uptake value, Upt fractional uptake per volume of tissue, TBU total fractional tumor uptake, LBM lean body mass estimate, BSA
body surface estimate
Werner R.A. et al.: Quantitative [68Ga] DOTATOC Biodistribution 793
Statistical Analysis
Statistical analysis was performed using SPSS Statistics 25.
Percentiles are reported to describe the distributions of the
parameters. Additionally, mean ± standard deviation is dis-
played for parameters if a normal distribution is not
excluded by the Shapiro-Wilk test. Spearman’s rank corre-
lation coefficient was used to assess the correlations between
parameters. Mann-Whitney U test was used to investigate
differences between tumor grading. A p value of less than
0.05 was assumed to be statistically significant.
Results
Patient Population
A total of 44 patients (21 females; median age 64 years;
mean age 62.4 ± 11.5 years; range 31–79 years) who
underwent [68Ga] DOTATOC were quantitatively analyzed.
Out of 44 (86.4 %), 38 had a history of gastroenteropancre-
atic NET (primary: ileum/jejunum/mesentery, 24/38,
63.2 %; pancreas, 10/38, 26.3 %; colon, 1/38, 2.6 %;
rectum, 3/38, 7.9 %). In the remaining 6/44 (13.6 %), a
neuroendocrine tumor of the lung (2/6, 33.3 %) or a cancer
of unknown primary (4/6, 66.7 %) had been diagnosed. The
clinical indication for imaging was evaluation of recurrent/
metastatic disease in the majority of patients (33/44,
75.0 %), while the remainder underwent [68Ga] DOTATOC
PET/CT for staging (11/44, 25.0 %). The median Ki67 was
4 % (mean, 5.3 ± 4.5 %). Out of 44 (47.7 %), 21 were G1
NET, while the remaining 23/44 (52.3 %) were G2 NET.
Out of 44 (86.4 %), 38 of the enrolled patients had
undergone previous therapy (surgery, 27/38 (71.1 %);
Bcold^ somatostatin analogues, 22/38 (57.9 %); PRRT, 15/
38 (39.5 %); chemotherapy, 8/38 (21.1 %); prior locore-
gional therapy, 3/38 (7.9 %); and tyrosine kinase inhibitor
therapy 1/38, (2.6 %)). The remaining 6/44 (13.6 %) were
treatment-naive at the time of imaging. Table 1 summarizes
these patients’ parameters.
Quantitative Assessment
In one patient, both adrenal glands were unidentifiable. The
right adrenal glands could not be identified in another two
patients (in all cases as a result of an inability to visually
separate the adrenal glands from adjacent organs on either
the PET or CT portion of the examination). The right kidney
could not be assessed in one patient due to a prior
nephrectomy, and in one case, a horseshoe kidney was
Fig. 1 Mean standardized uptake value (SUVmean; rhombs) and fraction of injected activity per kilogram of tissue (Upt; circles)
in normal organs (a kidneys, b spleen, c adrenals, and d liver) vs. decay corrected tumor fractional uptake (TBU).
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evaluated as a right kidney (due to the fact that the main part
of the organ was located in the right hemi-abdomen). Two
spleens could not be assessed due to splenectomy.
To generate the data for tumor burden in the 36 patients
demonstrating discernible, suspicious radiotracer uptake, a
total of 182 VOIs were placed (median, 4 per patient; range,
1–23). Of these VOIs, 56/182 (30.8 %) included metastases
in the skeleton, 53/182 (29.1 %) represented involved lymph
nodes, 38/182 (20.9 %) corresponded to liver lesions, 33/182
(18.1 %) were non-nodal soft tissue lesions, and 2/182
(1.1 %) were lung nodules. One patient with only two small
lesions G15 mm was excluded from SUV statistics.
Descriptive statistics are listed in Table 2. The median
SUVmean was 18.7 for the spleen, 9.2 for the kidneys, 6.8 for
the adrenal glands, and 5.6 for the liver. For tumor burden,
the median values were SUVmean: 6.9, SUVmax: 35.5, TBM:
42.6 g, and TBU: 1.2 %.
Correlative Analysis Table 3 lists Spearman’s rho for the
relations between normal organ parameters, the tumor
burden, and body size. The following significant relations
were observed: when comparing the organs, both spleen
SUVmean and Upt correlated positively with the
corresponding values in liver and kidneys. For the
adrenals, only Upt correlated with kidney Upt. Negative
correlation with TBU was observed for SUVmean in spleen
and adrenals.
With increasing volume of distribution, represented by
LBM and BSA, Upt decreased in kidneys, liver, and adrenal
glands and SUVmean increased in the spleen. Correlation
improved for the kidneys and the adrenals but not for liver
and spleen when the influence of the tumor uptake on the
activity available for organ uptake was taken into account by
the factor 1/(1-TBU). Figure 1 shows the observed SUVmean
and Upt vs. TBU for the evaluated organs. Figure 2 shows
the specific organ uptake Upt vs. BSA/(1-TBU); no
difference is visible in the distributions for patients with
minor (circles; TBU G 3 %) and higher tumor uptake
(rhombs; TBU 9 7 %).
In the groups of patients with tumor grade 1 and 2, there
were no differences in the SUV values according to the
Mann-Whitney U test. However, the total tumor mass tended
to be higher (P = 0.05) and TBU was higher (P = 0.03) in
patients with NET grade 2. Only one of eight patients with
negative PET was grade 2.
Figure 3 displays three patients with different tumor
burden (low, intermediate, high) and reflects visually that no
significant decrease in normal organ uptake is appreciated
with higher levels of tumor burden.
Fig. 2 Fraction of injected activity per kilogram of normal organ tissue (Upt) in a kidneys, b spleen, c adrenals, and d liver, in
patients with total tumor uptake TBU G 3 % (circles) and TBU 9 7 % (rhombs) as a function of the body surface area (BSA)
modified by the factor 1/(1-TBU).
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Discussion
In the present study in which the quantitative biodistribution
of [68Ga] DOTATOC was investigated in organs and
tumors, we were unable to generate evidence to suggest
that [177Lu] DOTATOC endoradiotherapy doses should be
modified on the basis of tumor burden. Although Spear-
man’s rank test identified some correlation between tumor
burden and normal abdominal organ uptake (Table 3), it can
be seen in Fig. 1 that the total tumor uptake TBU is neither
predictive for SUVmean nor for the activity uptake Upt in any
of the organs considered in this study.
Previously, the similar SSTR-targeted radiotracer [68Ga]
DOTATATE had demonstrated a tumor sink effect in a smaller
(n = 10) and more homogeneous patient cohort [9]. [68Ga]
DOTATATE has a higher affinity for the SSTR2A receptor
(IC50 0.2 nM vs. 2.5 nM for [
68Ga]DOTATOC) [17] and
median tumor uptake was higher in ref. [9] than in the present
study, presumably giving rise to a larger dynamic range within
a sink effect might be observed. Nevertheless, this effect was
observed in our study as well. As in [9], all coefficients of
correlation between the body size parameters and Upt were
negative for all abdominal organs (Table 3). Correlations
reached significance for kidneys, liver, and adrenal glands but
not for the spleen. The generally observed positive correlation
between SUVmean and the body size parameters LBM and BSA
was significant for the spleen only. However, compared to
Beauregard at al. [9], it is possible that the tumor burden of the
current patient cohort was relatively too low to observe a more
robust tumor sink effect.
It can be seen in Fig. 2 that the distributions of organ Upt vs.
BSA/(1-TBU) are not visibly different for patients with no or
minor tumor uptake and those with TBU 9 7 %, indicating that
the correlations observed in the present study are completely
explainable by the body size effect. Moreover, BSA/(1-TBU)
cannot be used to predict the activity concentration in the
kidneys (Fig. 2) and to modify the activity in a subsequent
treatment accordingly, as it has been suggested in [9].We agree
that it can be helpful, particularly for patients with high tumor
burden to adjust the therapy activity individually; however, the
large variation in data would lead to high and unjustified
corrections in many of the patients. Moreover, there is no
validated method to determine the kidney dose from PRRT in
advance from the activity concentration measured in PET.
Considering the [68Ga]/[177Lu] DOTATOC theranostics pair,
the physical half-life of Ga-68 is too short to predict biokinetics
with Lu-177 with sufficient accuracy. Therefore, we recom-
mend organ dosimetry with Lu-177 prior to the administration
of unusually high therapeutic activities.
As there was no meaningful effect of tumor burden on
normal organ uptake, this might also have implications for
Fig. 3 The [68Ga]DOTA-D-Phe-Tyr3-octreotide ([68Ga]DOTATOC) maximum intensity projection (MIP) of patients with a low
tumor burden, b intermediate tumor burden, and c high tumor burden. Spleen (S) and kidneys (K) are indicated. Threshold is set
to a SUV of 20 (screenshots of XD3 software, Mirada medical, Oxford, UK, are displayed). Red arrows indicate tumor lesions,
which can be detected on the MIP. a Several pulmonal lymph node metastases are indicated. b Lymph nodes, bone, and liver
lesions are marked. c The primary in the lung is highlighted. The uptake in normal organs (visible for liver, kidneys, and spleen)
does not differ among the different patients.
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the detection rate of tumor lesions, as the [68Ga] DOTA-
TOC background uptake is not reduced in patients with
high tumor burden (Fig. 3). This could potentially lead to
readers missing lesions with subtle uptake near sites of
significant tumor burden or normal organs with high
expression levels of SSTR2. This would likely be a rare
occurrence and would not affect staging in the vast
majority of patients; however, a whole-body assessment
with an SSTR-targeted PET imaging agent may benefit
from the incorporation of structured reporting guidelines
that include a measure of uncertainty when characterizing
lesions [12].
In regard to our hypothesis that tumor grading may be
suggested by PET findings, one of our intentions was to find
a relationship between tumor grade and the activity
distribution. Uptake in the abdominal organs turned out to
be independent of grading. High tumor mass and uptake
mitigated against, and a negative PET favored, grade 1. An
attempt to reproduce tumor stage from the information
deduced from PET imaging by a logistic binary regression
resulted in a rate of correct prediction of less than 70 % (data
not shown). It can therefore be concluded that PET is
inadequate to identify or modify tumor grading non-
invasively.
A limitation regarding the validity of the present study
is that most of the patients in the cohort were heavily
pretreated, which might have potentially biased the derived
uptake values [18]. However, this enrolled cohort of
randomly selected patients is reflective of a Breal-world^
clinical scenario in which patients being evaluated for
PRRT will often have undergone prior treatments. More-
over, the herein obtained SUVs are generally similar to
those reported from other studies using [68Ga]DOTA-based
agents; compared to previous studies using [68Ga] DOTA-
TOC, we derived almost identical values for normal organs
(e.g., for the spleen) [19, 20]. However, a dosimetry
assessment with [177Lu] DOTATOC is definitely war-
ranted to further explore whether a potential tumor sink
effect exists with this radiotracer in a therapeutic setting.
Apart from that, metastases smaller than 15 mm were
excluded in the present investigation because of a potential
PVE. However, a potential spill-in/spill-out phenomenon,
possibly partially compensating for PVE, has been de-
scribed for 2-deoxy-2-[18F]-fluoro-D-glucose and such an
effect should be investigated for SSTR-targeted radio-
tracers as well [21].
Conclusion
In quantitative assessment of [68Ga] DOTATOC PET/CT,
we found no significant effect of the tumor burden or the
grading on normal organ uptake in a typical cohort of NET
patients. [68Ga] DOTATOC PET/CT is inadequate to
identify or modify tumor grading or serve as a substitute
for dosimetry in order to justify administration of unusually
high treatment activities.
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